tbuckley/cabot-search huggingface dataset:
PWE-037 Role of ct angiography in the management of acute gi bleeding
Authors: PD Mooney, K Kodali, C Toh, N Hersey, J Adiotomre, H Penny, M Kurien, DS Sanders
Journal: Gut (2015)

<h3>Introduction</h3> Gastrointestinal (GI) bleeding cannot always be controlled or identified at endoscopy (OGD), therefore guidelines recommend radiological intervention in an unstable patient. The options are fluoroscopic angiogram (FA) which is time consuming, requires significant expertise, and has significant radiation exposure. Alternatively a CT angiogram (CTA) may offer a sensitive, rapid diagnosis of the source of GI bleeding to allow definitive treatment. Data on the role and diagnostic yield of CTA are lacking. We present the largest international study to assess the impact of CTA in upper GI bleeding. <h3>Method</h3> A retrospective analysis of endoscopy and radiology databases was used to identify patients who underwent radiological intervention for GI bleeding at Sheffield Teaching Hospitals between 2003 and 2013. A control group of 757 patients (who did not undergo FA or CTA) from the South Yorkshire GI bleed audit 2011 was used for comparison. Pre-endoscopy Rockall scores, routine haematology and biochemistry results taken prior to endoscopy and inpatient mortality rates were compared. <h3>Results</h3> 59 patients (35 male, mean age 69.3) underwent imaging for upper GI bleeding during the study period. In 49/59 (mean age=68.3, mean Rockall = 3.8, mean Hb = 84.7) a source was initially identified at OGD but with continued bleeding. CTA was performed in 31 with the other 18 having immediate FA. For patients having a CTA first a source was identified in 15 (48%) requiring embolization in 10. 4 patients who did not have an abnormality seen on CTA subsequently required FA and embolization and 2 of these patients died. For the other 10/59 (16.9%) (mean age 74.3 mean Rockall=4, mean Hb=84.2) no source was identified at OGD and they underwent CTA identifying 8 bleeds which proceeded to FA and then embolization in 6. Inpatient mortality in this group was 50% which was significantly higher than 14.3% for those patients with an identified source for upper GI bleed (p = 0.02). Patients who underwent CTA were older (p = 0.039) and presented with higher median pre-endoscopy Rockall scores (p = 0.003) than controls. Both CTA and ‘direct to FA patients’ presented with lower Hb (p &lt; 0.0001) than controls. There was no significant difference between CTA and FA patients. Inpatient mortality rates were higher in those who underwent CTA prior to FA (22%) compared to those who went directly to FA (11%) but this was not significant (p = 0.5). <h3>Conclusion</h3> Radiological imaging resulted in embolization in 55.9% of patients referred. Patients requiring radiological intervention for GI bleeds have more significant bleeding with lower haemoglobin and higher Rockall scores. Patients with no source of bleeding on OGD have higher inpatient mortality despite radiological intervention. <h3>Disclosure of interest</h3> None Declared.
Tension Pneumoperitoneum
Authors: Haytham M A Kaafarani
Journal: New England Journal of Medicine (2015)

A 65-year-old woman who had undergone colonoscopy with removal of polyps became unresponsive at the end of the procedure. The abdomen was massively distended, tympanitic, and tender to palpation. The patient underwent a decompressive laparotomy, shown in a video.
Survivorship: Screening for Cancer and Treatment Effects, Version 2.2014
Authors: Crystal S. Denlinger, Jennifer A. Ligibel, Madhuri Are, K. Scott Baker, Wendy Demark-Wahnefried, Don Dizon, Debra L. Friedman, Mindy Goldman, Lee Jones, Allison King, Grace H. Ku, Elizabeth Kvale, Terry S. Langbaum, Kristin Leonardi-Warren, Mary S. McCabe, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Mary Ann Morgan, Javid J. Moslehi, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, Muhammad Raza, M. Alma Rodriguez, Karen L. Syrjala, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole R. McMillian, Deborah A. Freedman-Cass
Journal: Journal of the National Comprehensive Cancer Network (2014)

The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for common physical and psychosocial consequences of cancer and cancer treatment. This portion of the guidelines describes recommendations regarding screening for the effects of cancer and its treatment. The panel created a sample screening tool, specifically for use in combination with the NCCN Guidelines for Survivorship, to guide providers to topics that require more in-depth assessment. Effective screening and assessment can help providers deliver necessary and comprehensive survivorship care.
Respiratory Care of the Patient with Duchenne Muscular Dystrophy
Authors: Jonathan D Finder, David Birnkrant, John Carl, Harold J Farber, David Gozal, Susan T Iannaccone, Thomas Kovesi, Richard M Kravitz, Howard Panitch, Craig Schramm, Mary Schroth, Girish Sharma, Lisa Sievers, Jean M Silvestri, Laura Sterni
Journal: American Journal of Respiratory and Critical Care Medicine (2004)
OP0055 Anti-RNA Polymerase III Antibodies in Patients with Systemic Sclerosis: A Eustar Multicenter Collaborative Study
Authors: M.G. Lazzaroni, E. Colombo, I. Cavazzana, O. Distler, R. Hesselstrand, V. Smith, P. Caramaschi, E. Hachulla, A. Balbir-Gurman, K. Romanowska-Pròchnicka, V. Riccieri, Y. Allanore, P. Airo'
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Most data on the clinical associations of anti-RNA polymerase III (RNAP) antibodies in patients with Systemic Sclerosis (SSc) derive from single-center studies or relatively small positive case number reports. <h3>Objectives</h3> To analyse the clinical associations of anti-RNAP in a large cohort of patients with different geographic and ethnic origin using the multicenter EUSTAR database. <h3>Methods</h3> Patients from the EUSTAR database were included when the item anti-RNAP was fulfilled in at least one visit, and considered anti-RNAP+ when scored positive in at least one determination. In a second phase, EUSTAR centers were asked to participate to a case-control study, fulfilling a supplementary form dedicated to skin involvement progression, gastric antral vascular ectasia (GAVE), and malignancies. Malignancies diagnosed between 6 months before and 12 months after the onset of SSc were defined as "synchronous to the onset of SSc". Centers were asked to match anti-RNAP+ cases with anti-RNAP- SSc controls, paired for sex, cutaneous subset, and disease duration. Univariate methods were used to compare patients with and without anti-RNAP. <h3>Results</h3> Among 11,399 SSc patients registered in the EUSTAR database, 4,986 had anti-RNAP antibodies status available including 223 anti-RNAP+ (4.5%) and 4,763 anti-RNAP-. The differences between the two groups are shown in Figure 1. There was no difference as far as ethnicity (Caucasians: 94.2% vs 95.0%), age at disease onset, disease duration, length of follow-up, and other parameters included in the database. Ten centers participated in the case-control study, collecting 126 anti-RNAP+ cases (23% male, 59% with diffuse cutaneous involvement), and 137 anti-RNAP- matched patients. A trend toward a higher peak of modified Rodnan Skin Score (RSS) in anti-RNAP+ patients was observed (p:0.07). Interval time between the first symptom of SSc other than Raynaud9s phenomenon and the peak of RSS was shorter in anti-RNAP+ cases than in controls (p:0.008; log-rank test). Other differences between the two groups are shown in Figure 1. <h3>Conclusions</h3> Analysis of a large, multicenter database and a dedicated case-control study confirm that anti-RNAP is one of the most useful markers available to stratify SSc patients in subsets with peculiar clinical features. These include rapid progression of skin involvement, GAVE, and an increased risk of diagnosis of cancer simultaneous to the onset of SSc. This information should guide monitoring and follow-up in anti-RNAP+ SSc patients. <h3>Disclosure of Interest</h3> None declared
Frozen Blood
Authors: C. Robert Valeri
Journal: New England Journal of Medicine (1966)

Importance of Removing Glycerol from the Red CellsWhen red cells that have been stored with glycerol are to be transfused, it is necessary to reduce their glycerol content to about 2 per cent; otherwise, they will hemolyze on contact with plasma.30 Numerous methods have been proposed to remove this penetrating additive.Mollison and Sloviter76 removed the glycerol by a dialysis procedure that was both slow and cumbersome. Lovelock83 proposed a washing technic using hypertonic citrate to crenate the red cells, resulting in removal of a considerable portion of the intracellular glycerol. Brown and Hardin79 advocated multiple washes in successively . . .
Induction of the 5S RNP–Mdm2–p53 ribosomal stress pathway delays the initiation but fails to eradicate established murine acute myeloid leukemia
Authors: P Jaako, A Ugale, M Wahlestedt, T Velasco-Hernandez, J Cammenga, M S Lindström, D Bryder
Journal: Leukemia (2016)
On the Type of Hemoglobin in the Neoplastic Cell of Virus-Induced Fowl Erythroleukemia2
Authors: E. Ambs, B. Thorell
Journal: JNCI Journal of the National Cancer Institute (1960)

The virus-induced fowl erythroleukemic cell may contain as much as one third of the hemoglohin content in the normal fowl erythrocyte (about 10 and 30 picograms of hemoglobin per cell, respectively). The hemoglobin prepared from erythroleukemic cells has been analyzed by paper- and starch-bloc electrophoresis and also with its alkali-denaturation kinetics. Erythrocyte hemoglobin preparations from normal birds and from the remaining normal erythrocytes in leukemic birds served as comparison material. The normal erythrocytes from both normal and leukemic birds showed two distinct hemoglobin components, I and II, of which component II accounts for 20 to 40 percent of the total. Hemoglobin prepared from erythroleukemic cells showed the same two types and in the same proportions as those of the normal erythrocyte hemoglobin. This indicated that the hemoglobin synthesis during the neoplastic cell development induced by the leukemia virus was under a similar genetic control as during the normal red-cell development.
Observations on the Energy Metabolism of Rats Receiving Walker Tumor 256 Transplants
Authors: A. W. Pratt, F. K. Putney
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article Observations on the Energy Metabolism of Rats Receiving Walker Tumor 256 Transplants Get access A. W. Pratt, A. W. Pratt Laboratory of Physiology, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar F. K. Putney F. K. Putney Laboratory of Physiology, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 1, January 1958, Pages 173–187, https://doi.org/10.1093/jnci/20.1.173 Published: 01 January 1958 Article history Received: 01 August 1957 Published: 01 January 1958
FRI0462 Does Serum NT-Probnp Test Facilitate Diagnosis of PAH in Patients with SSC?:
Authors: E. Nikolaeva, E. Alexandrova, A. Novikov, I. Kurmukov, N. Yudkina, D. Novikova, A. Volkov
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Pulmonary arterial hypertension (PAH) is a progressive vasculopathy that is advanced by the time symptoms develop. Screening can help; however, multiple investigations, including annual echocardiography, DLCO etc., have low specificity and may not be cost-effective. <h3>Objectives</h3> We sought to evaluate the predictive level and accuracy of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) in a screening for SSc-PAH. <h3>Methods</h3> We studied 65 SSc patients with various forms of PH and 25 SSc patients without PH, confirmed by right heart catheterization (RHC). SSc was diagnosed in accordance with EULAR/ACR criteria (2013). Demographics studies, physical examination, vital signs measurement, 6-minute walk test, echocardiography, pulmonary function testing, and biomarker levels (N-terminal pro-brain natriuretic peptide [NT-proBNP] and uric acid) were done within 24 hours before RHC. We got 4 groups of patients <h3>Results</h3> Age differences were not significantly. NT-proBNP levels didn9t differ in groups PAH-SSc and PH-LHD, and were significantly higher than in other groups (* - p&lt;0,0001). NT-proBNP correlated with NYHA functional class (r 0.57; p 0.00002), 6-MWT (r -0.58; p 0.000009), uric acid level (r 0.56; p 0.00002), right atrial pressure (r 0.43; p 0.002), mean pulmonary artery pressure (r 0.49; p 0.0004), cardiac output (r -0.53; p 0.0002), pulmonary vascular resistance (r 0.65; p 0.000001), SSc-severity index (r 0.44; p 0.003) and presence of signs of the heart failure (peripheral oedema (p 0.00002) and GFR decrease (p 0.008)). ROC curve analyses were performed to determine the optimal cut-off point for NT-proBNP and other variables in prediction of PAH. NT-proBNP at the level of &gt;252,5 pg/mL, predicts the presence of SSc-PAH with sensitivity of 82% and specificity of 72%; positive predictive value for SSc-PAH was 86,6%, negative predictive value – 72,4%; risk of PAH was 3.66-fold higher than for other forms PH (95%CI 1.45; 9,21) (p=0.0059). Hazard ratio for PH-LHD was 4.99 (95% CI 0.61;40,59). Unfortunatelly, this fact was not significant (p=0.13). <h3>Conclusions</h3> Increased serum NT-proBNP can be considered as detecting factor of SSc-PAH provided left heart diseases are excluded. <h3>Disclosure of Interest</h3> None declared
Paclitaxel plus Bevacizumab for Metastatic Breast Cancer
Authors: Antonio Rossi, Valter Torri, Cesare Gridelli
Journal: New England Journal of Medicine (2008)

To the Editor: On the basis of an increase in progression-free survival of 5.9 months, Miller et al. (Dec. 27, 2007, issue)1 imply that the addition of bevacizumab to paclitaxel is a significant advance in the treatment of metastatic breast cancer. However, progression-free survival is an unreliable measure of benefit in metastatic cancer, and patients given bevacizumab do not live longer than patients given paclitaxel alone. Furthermore, it is questionable to cite response rates in phase 3 studies, since response rates are a means of looking for active new agents in phase 2 studies. Finally, there are no data that justify a dose of bevacizumab greater than 3 mg per kilogram of body weight in phase 3 studies2; a dose that adds to cost and potential toxicity. Crucially, the data reported by Miller et al. reveal no correlation between progression-free survival or response rates and overall survival or quality of life. What, then, are the benefits of this treatment?
Case 7-1971
Authors: Richard C. Cabot, Benjamin Castleman, Betty U. McNeely, Allan L. Friedlich, James B. Caulfield, Benjamin Castleman
Journal: New England Journal of Medicine (1971)

Presentation of CaseA 65-year-old woman was admitted to the hospital because of acute pulmonary edema.Twenty years earlier she was found to have diabetes and was managed on NPH insulin, 20 U daily. During the 18 months before admission she experienced recurrent "pressing" pain in the left precordial area on exertion, with relief by rest and by nitroglycerin. Five months before entry she began to have recurrent bouts of severe anorexia and nausea, with abdominal distention, crampy periumbilical pain and constipation, accompanied by worsening of the chest pain. One month thereafter an upper gastrointestinal series and oral cholecystograms were . . .
Endoscopic ultrasound-guided therapy of a gastrointestinal stromal tumor (GIST)
Authors: Eduardo Valdivielso Cortázar, Ignacio Fernández-Urién, Juan Vila Costas, Francisco Jiménez Pérez
Journal: Endoscopy (2015)

A 90-year-old man was admitted to our hospital because of recurrent upper gastrointestinal bleeding due to a 5-cm gastrointestinal stromal tumor (GIST) in the lesser curve of the stomach ([Fig. 1]). After conventional endoscopic sclerotherapy failed to achieve a response, and because of the patient's condition, it was decided to perform endoscopic ultrasound (EUS)-guided therapy.
AB0687 Non-Invasive Assessment of Muscle Quality by MRI as a Potential Marker of Disease Modification in Bimagrumab-Treated SIBM Patients
Authors: D. Laurent, B. Tseng, S. Greenberg, P. Houston, D. Papanicolaou, R. Roubenoff
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Bimagrumab is a monoclonal antibody that inhibits ligand binding to the activin receptor IIA/B thereby stimulating muscle growth. In a proof of concept study, bimagrumab increased thigh muscle volume (TMV) by 6.5% (p=0.024) and decreased intramuscular adipose tissue (IMAT) by 3% (p=n.s.) after 8 weeks of treatment. <h3>Objectives</h3> Using qualitative muscle MRI to characterize disease severity and modification in sporadic inclusion body myositis (sIBM) patients treated with bimagrumab. <h3>Methods</h3> 14 patients were randomized to single IV dose (30 mg/kg) of bimagrumab (n=11) or placebo (n=3). Disease severity was assessed by visual scoring of PD images. TMV, IMAT, subcutaneous (SC) adipose tissue volume, and individual muscle volume (IMV) were determined from proton-density (PD) MR images using semi-automated segmentation approaches. In addition, the relative fat fraction (%FF) and apparent coefficient of diffusion (ADC) were measured from three-point Dixon and diffusion-weighted images, respectively. <h3>Results</h3> After 8 weeks of treatment, mean score for disease activity (21.5±0.6) remained unchanged. Although insignificant, decrease in %FF (−7% vs baseline) was seen at Week-8 in 4 patients while SC and IMAT volumes were slightly reduced. At baseline, fat-infiltrated muscles had lower ADC values than previously reported (1.46±0.11 vs 1.62±0.14 x10<sup>-3</sup> mm<sup>2</sup>/sec) and a trend towards normal values was observed after treatment. At baseline, IMAT content was greater in anterior than in posterior thigh muscles (49% vs 23%, p&lt;0.01). Individual muscle volumes (IMV) increased more in the posterior (+8%) than in anterior thigh compartment (+4%, p&lt;0.01). At Week-16, further decrease in IMAT in all muscles (-7% vs baseline, p&lt;0.05) correlated well with the change from baseline in IMV at Week-8 (r=0.57, p&lt;0.05). <h3>Conclusions</h3> MRI may be used in a comprehensive non-invasive way to demonstrate potential of bimagrumab as a disease-modifying therapy which may potentially lead to restoration of normal muscle quality and composition. <h3>References</h3> Amato AA et al. Neurology. 2014;83(24):2239-46. Qi J et al. J Magn Reson Imaging. 2008;27(1):212-7. <h3>Acknowledgements</h3> Study Supported By: Novartis Pharma AG <h3>Disclosure of Interest</h3> D. Laurent Shareholder of: Novartis, Employee of: Novartis Institutes for Biomedical Research, Basel, Switzerland, B. Tseng Employee of: Novartis Institutes for Biomedical Research, Cambridge, USA, S. Greenberg Grant/research support from: Novartis Pharma AG, P. Houston Employee of: Novartis Pharma AG, Basel, Switzerland, D. Papanicolaou Employee of: Novartis Pharmaceuticals Corporation, East Hanover, USA, R. Roubenoff Employee of: Novartis Institutes for Biomedical Research, Basel, Switzerland.
A Study of the Penn-Hall Seroflocculation Reaction for Cancer&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: A C PEACOCK, G Z WILLIAMS
Journal: JNCI Journal of the National Cancer Institute (1957)

A Study of the Penn-Hall Seroflocculation Reaction for Cancer Get access Andrew C. Peacock, Andrew C. Peacock Clinical Trials Unit, National Cancer Institute,3 and Clinical Pathology Department, Clinical Center, Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar George Z. Williams George Z. Williams Clinical Trials Unit, National Cancer Institute,3 and Clinical Pathology Department, Clinical Center, Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 18, Issue 2, February 1957, Pages 277–283, https://doi.org/10.1093/jnci/18.2.277 Published: 01 February 1957 Article history Received: 13 July 1956 Published: 01 February 1957
Physiotherapy and Occupational Therapy and Mild to Moderate Parkinson Disease
Authors: Régis Gemerasca Mestriner
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Genomic <i>EWSR1</i> Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma
Authors: Manuela Krumbholz, Julia Hellberg, Benedikt Steif, Tobias Bäuerle, Clarissa Gillmann, Torsten Fritscher, Abbas Agaimy, Benjamin Frey, Joerg Juengert, Eva Wardelmann, Wolfgang Hartmann, Heribert Juergens, Uta Dirksen, Markus Metzler
Journal: Clinical Cancer Research (2016)

The application of the tumor-specific genomic fusion sequence as noninvasive biomarker for therapy monitoring in Ewing sarcoma (EwS) has been evaluated.EwS xenograft mouse models were used to explore detectability in small plasma volumes and correlation of genomic EWSR1-FLI1 copy numbers with tumor burden. Furthermore, 234 blood samples from 20 EwS patients were analyzed before and during multimodal treatment. EWSR1 fusion sequence levels in patients' plasma were quantified using droplet digital PCR and compared with tumor volumes calculated from MRI or CT imaging studies.Kinetics of EWSR1 fusion sequence copy numbers in the plasma are correlated with changes of the tumor volume in patients with localized and metastatic disease. The majority of patients showed a fast reduction of cell-free tumor DNA (ctDNA) during initial chemotherapy. Recurrence of increasing ctDNA levels signalized relapse development.Genomic fusion sequences represent promising noninvasive biomarkers for improved therapy monitoring in EwS. Until now, response assessment is largely based on MRI and CT imaging, implying restrictions on closely repeated performance and limitations on the differentiation between vital tumor and reactive stromal tissue. Particularly in patients with prognostic unfavorable disseminated disease, ctDNA is a valuable addition for the assessment of therapy response. Clin Cancer Res; 22(17); 4356-65. ©2016 AACR.
Changing Adjuvant Breast-Cancer Therapy with a Signal for Prevention
Authors: Rowan T. Chlebowski, Matthew J. Budoff
Journal: New England Journal of Medicine (2016)

Five randomized, full-scale studies have reported that 10 years of adjuvant endocrine therapy is beneficial for postmenopausal women with hormone-receptor–positive breast cancer. However, no prior study has involved more than 5 years of aromatase-inhibitor use or assessed a duration of adjuvant endocrine therapy of more than 10 years.1 Goss and colleagues2 now provide results from the MA.17R trial supporting the use of an aromatase inhibitor for 10 years and the use of adjuvant endocrine therapy for even longer total durations. The beneficial effects of increasing disease-free survival, with a favorable toxicity profile for continuing the aromatase inhibitor letrozole for 5 . . .